2 results match your criteria: "Cancer Center of Hebei Province and The Fourth Hospital of Hebei Medical University[Affiliation]"
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
J Clin Oncol
October 2019
National Cancer Center, State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Purpose: Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study.
Patients And Methods: Chinese patients with HER2-positive relapsed or metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400 mg pyrotinib or lapatinib 1,250 mg orally once per day for 21-day cycles in combination with capecitabine (1,000 mg/m orally twice per day on days 1 to 14).
Incidence rate of female breast cancer in urban Shijiazhuang in 2012 and modifiable risk factors.
Thorac Cancer
September 2016
Department of Cancer Research, Cancer Center of Hebei Province and The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Background: Breast cancer is diagnosed more frequently among urban than rural women in China; however, the incidence among women in Shijiazhuang is unknown.
Methods: As registered Chinese citizens are entitled to complete public medical insurance coverage, the incidence rate was estimated using reimbursement records of first hospitalization.
Results: Breast cancer is the most common cancer among women in Shijiazhuang.